AbbVie says Phase 3 trials show Rinvoq vitiligo repigmentation gains extend to week 76

By Public Technologies
  • AbbVie disclosed long-term Phase 3 Viti-Up results for RINVOQ in non-segmental vitiligo, presented at the 2026 EADV Congress.
  • Patients who stayed on treatment showed continued improvement in facial and overall skin repigmentation through 76 weeks.
  • A phototherapy substudy presented week-28 findings showing stronger repigmentation trends when RINVOQ was combined with NB-UVB versus RINVOQ alone.
  • Safety through 76 weeks aligned with the established profile for upadacitinib, with no new safety signals reported.
  • RINVOQ is cleared in the EU for eligible adults and adolescents with non-segmental vitiligo; U.S. regulatory review is ongoing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610011000PR_NEWS_USPR_____CG57273) on October 01, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.